Company Overview

Company name: Canntab Therapeutics (CNQ: PILL)
Description: Canntab Therapeutics Ltd is a Canadian cannabis oral dosage formulation company based in Markham Ontario, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids. It has developed in-house technology to deliver standardized medical cannabis extract from selective strains in a variety of extended/sustained release pharmaceutical dosages for therapeutic use.
Year founded: 2010
Parent company:
Industry: Healthcare | Group: | Code:
Employees: 5
City: Markham
State: Ontario
Country: Canada

Financial Highlights

Start up capital raised (USD Million): 3.73
Business status: Generating Revenue/Not Profitable
Ownership: Publicly Held
Exchange: CNQ
Ticker: PILL
Revenue (USD Million): 0.27
Gross profit (USD Million):
Net income (USD Million) -1.85
Enterprise value: 7.96
Earnings before interest, tax, depreciation and amortization (EBITDA): -1.78
Fiscal period: TTM 1Q2020
Financing Status: The company (CNQ:PILL) received $3.73 million of development capital from undisclosed investors on March 16, 2020 through a private placement. The proceeds from the placement will be used for company’s expansion through its wholly owned US subsidiary Canntab USA, Inc. into the State of Florida jointly with Exactus Inc. for the manufacture of a CBD hard pill (non-THC) in formulations for sale and distribution across the United States; A trial with the University of British Columbia to research the effect of opioid sparing high formulation with Canntab’s bi-layered CBD/THC controlled release formulations for post-operative pain care; Clinical 3-way crossover blood level study to further the Company’s research of its solid oral dose formulations, including extended release, immediate release, and multi-particulate formulations; Expansion of the company’s facility in Markham, Ontario Canada; Chemistry analysis and third-party testing of products for New Cannabis Product applications for Health Canada; Manufacturing inputs needed to build inventory of products for sale and distribution and General working capital purposes.
Number of active investors:
Profile last updated: 16-Apr-2020
Last known valuation:
Last known valuation date: